Oncology and Melanoma
Clinical research includes metastatic melanoma, with attention to treatment strategies used after disease stabilization on PD-1 inhibitor therapy. The sponsor’s oncology portfolio also extends to advanced solid tumours involving the central nervous system.
- Metastatic melanoma
- PD-1 inhibitor therapy
- Central nervous system involvement
Research activity in this area reflects interest in immuno-oncology and in treatment approaches for difficult-to-manage metastatic disease.
Brain Metastasis in Non-Small-Cell Lung Cancer
The sponsor supports studies in non-squamous non-small-cell lung cancer with brain metastases, focusing on combined systemic treatment approaches for intracranial disease control and broader cancer management.
- Non-squamous NSCLC
- Brain metastases
- Immunotherapy combinations
This area highlights involvement in metastatic lung cancer with neurological spread and the clinical challenges associated with central nervous system disease.
Kidney Transplantation
Research activity includes prophylaxis of transplant rejection in adult kidney allograft recipients, with a focus on maintenance immunosuppression and post-transplant graft protection.
- Kidney allograft recipients
- Transplant rejection prophylaxis
- Tacrolimus formulations
The sponsor’s transplant portfolio addresses immunological control after renal transplantation and the use of oral immunosuppressive therapy.
Liver Transplantation
Clinical studies also cover prophylaxis of transplant rejection in adult liver allograft recipients, with interest in immunosuppressive management after hepatic transplantation.
- Liver allograft recipients
- Hepatic transplantation
- Tacrolimus bioavailability
These trials reflect a therapeutic focus on preserving graft function and evaluating oral calcineurin inhibitor treatment in the transplant setting.
